secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001193125-23-203000
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns CEO Senthil Sundaram resigns for health reasons; Erin Quirk assumes leadership as principal executive officer
--------------------------------------------------------------------------------

- Senthil Sundaram resigned as CEO and Board member due to health reasons previously disclosed in January 2022.
- Erin Quirk, M.D., President and Head of R&D, assumed leadership effective immediately as principal executive officer.
- Sundaram will remain as a Senior Advisor to the company.
- Company plans three key clinical data readouts across three programs by end of 2024; balance sheet supports milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000119312523203000/0001193125-23-203000-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000119312523203000/d509174d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-203000

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer